1 Comprehensive Epitope Mapping of Broad Sarbecovirus Neutralizing Antibodies

2 Yunlong Cao^{1,2,#,*}, Ayijiang Yisimayi^{2,3,#}, Fanchong Jian^{2,4,#}, Tianhe Xiao^{2,5,#}, Weiliang
3 Song^{2,3,#}, Jing Wang^{2,3,#}, Shuo Du^{3,#}, Zhiying Zhang^{3,#}, Pulan Liu^{3,#}, Xiaohua Hao^{6,#},
4 Qianqian Li^{7,#}, Peng Wang¹, Ran An², Yao Wang¹, Jing Wang¹, Haiyan Sun¹, Lijuan
5 Zhao¹, Wen Zhang⁶, Dong Zhao⁶, Jiang Zheng¹, Lingling Yu¹, Can Li¹, Na Zhang¹, Rui
6 Wang¹, Xiao Niu², Sijie Yang^{2,8}, Xuetao Song¹, Linlin Zheng¹, Zhiqiang Li^{8,9},
7 Qingqing Gu¹, Fei Shao¹, Weijin Huang⁷, Youchun Wang⁷, Ronghua Jin^{6,*}, Junyu
8 Xiao^{3,8,9,*}, Xiaoliang Sunney Xie^{1,2,*}

9

10 ¹Changping Laboratory, Beijing, P.R. China.

11 ²Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R.
12 China.

13 ³School of Life Sciences, Peking University, Beijing, P.R. China.

14 ⁴Joint Graduate Program of Peking-Tsinghua-NIBS, Academy for Advanced
15 Interdisciplinary Studies, Peking University, Beijing, China.

16 ⁵College of Chemistry and Molecular Engineering, Peking University, Beijing, P.R.
17 China.

18 ⁶Beijing Ditan Hospital, Capital Medical University, Beijing, P.R. China.

19 ⁷Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological
20 Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P.R.
21 China.

22 ⁸Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, P.R. China

23 ⁹Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, P.R.
24 China.

25 *Correspondence: Yunlong Cao (yunlongcao@pku.edu.cn); Ronghua Jin
26 (ronghuajin@ccmu.edu.cn); Junyu Xiao (junyuxiao@pku.edu.cn); Xiaoliang Sunney
27 Xie (sunneyxie@biopic.pku.edu.cn)

28 [#]These authors contributed equally.

29

30

Abstract

Constantly emerging SARS-CoV-2 variants, such as Omicron BA.1, BA.1.1 and BA.2, pose a severe challenge to COVID-19 control¹⁻¹⁰. Broad-spectrum antibody therapeutics and vaccines are needed for defending against future SARS-CoV-2 variants and sarbecovirus pandemics¹¹⁻¹⁴; however, we have yet to gain a comprehensive understanding of the epitopes capable of inducing broad sarbecovirus neutralization. Here, we report the identification of 241 anti-RBD broad sarbecovirus neutralizing antibodies isolated from 44 SARS-CoV-2 vaccinated SARS convalescents. Neutralizing efficacy of these antibodies against D614G, SARS-CoV-1, Omicron variants (BA.1, BA.1.1, BA.2), RATG13 and Pangolin-GD is tested, and their binding capability to 21 sarbecovirus RBDs is measured. High-throughput yeast-display mutational screening was further applied to determine each antibody's RBD escaping mutation profile, and unsupervised epitope clustering based on escaping mutation hotspots was performed^{7,15-18}. A total of 6 clusters of broad sarbecovirus neutralizing antibodies with diverse breadth and epitopes were identified, namely Group E1 (S309¹⁹, BD55-3152 site), E3 (S2H97²⁰ site), F1 (CR3022²¹, S304²² site), F2 (DH1047²³, BD55-3500 site), F3 (ADG-2²⁴, BD55-3372 site) and B' (S2K146²⁵ site). Members of E1, F2 and F3 demonstrate the highest neutralization potency; yet, Omicron, especially BA.2, has evolved multiple mutations (G339D, N440K, T376A, D405N, R408S) to escape antibodies of these groups. Nevertheless, broad sarbecovirus neutralizing antibodies that survived Omicron would serve as favorable therapeutic candidates. Furthermore, structural analyses of selected drug candidates propose two non-competing antibody pairing strategies, E1-F2 and E1-F3, as broad-spectrum antibody cocktails. Together, our work provides a comprehensive epitope map of broad sarbecovirus neutralizing antibodies and offers critical instructions for designing broad-spectrum vaccines.

61 Main

62 The recent emergence and global spreading of severe acute respiratory syndrome
 63 coronavirus 2 (SARS-CoV-2) variant Omicron has posed a critical challenge to the
 64 efficacy of COVID-19 vaccines and neutralizing antibody therapeutic²⁻⁵. Due to
 65 multiple mutations to the spike protein and its receptor-binding domain (RBD),
 66 Omicron can cause severe neutralizing antibody evasion⁵⁻⁹. The continuous evolution
 67 of Omicron, such as BA.1.1 and BA.2, may lead to an even stronger immune escape^{2,8,10}.
 68 For pandemic preparedness, pan-sarbecovirus therapeutics and vaccines that are
 69 effective against future SARS-CoV-2 variants and other sarbecoviruses are urgently
 70 needed¹¹⁻¹⁴. Several broad sarbecovirus neutralizing antibodies have been reported^{20,23-}
 71 ³⁴; however, since the number of antibodies studied has been limited, we still lack a
 72 comprehensive understanding of the RBD epitopes that could induce broad
 73 sarbecovirus neutralizing antibodies.

74 SARS convalescents who were subsequently vaccinated against SARS-CoV-2 may
 75 carry a large number of broad-spectrum neutralizing antibodies^{19,23,35}. To study their
 76 antibody repertoire, we recruited 44 SARS convalescents and collected their plasma
 77 and peripheral blood mononuclear cells (PBMCs) after SARS-CoV-2 vaccination
 78 (Supplementary Table 1). The plasma of these individuals exhibited high neutralization
 79 ability against both SARS-CoV-1 and SARS-CoV-2 pseudovirus (Extended Data Fig
 80 1a,b). Using flow cytometry, we sorted the memory B cells that could cross-bind to
 81 both SARS-CoV-1 and SARS-CoV-2 RBD (Extended Data Fig. 2). Then, we used high-
 82 throughput single-cell VDJ sequencing to obtain the B-cell repertoire of these memory
 83 B cells^{36,37}, and expressed the selected IgG antibodies *in vitro* as human IgG1
 84 monoclonal antibodies. In total, we obtained 1409 SARS-CoV-1 and SARS-CoV-2
 85 RBD binding IgG1 antibodies, where 269 showed SARS-CoV-1 and SARS-CoV-2
 86 cross-neutralizing capability (Supplementary Table 2).

87 To study the epitope distribution of those bivalent antibodies, we analyzed their
 88 escaping mutation profiles using high-throughput yeast display mutant screening that

covers all possible single residue substitutions in the wildtype RBD background^{7,15-18}. We successfully retained the escaping mutation profiles of 241 SARS-CoV-1/SARS-CoV-2 cross-neutralizing antibodies as well as 85 non-neutralizing bivalent binding antibodies. Combined with previously characterized antibodies isolated from SARS-CoV-2 convalescents and vaccinees^{36,38,39}, we collected a library of 715 human SARS-CoV-2 IgG1 antibodies with corresponding escaping mutation profiles (Supplementary Data 1). Neutralizing efficacy of these antibodies against sarbecovirus, including D614G, SARS-CoV-1, Omicron variants (BA.1, BA.1.1, BA.2), RATG13 and Pangolin-GD, is tested, and their binding capability to 21 sarbecovirus RBD is measured through ELISA (Supplementary Table 2-3). Based on the escaping mutation profiles, the antibodies could be unsupervised clustered into 10 epitope groups (Fig. 1a, Extended Data Fig. 3, Supplementary Data 2), as described previously⁷. Group A-D recapitulates our previous antibody clustering⁷, in which the members mainly target the ACE2-binding motif^{11,22,40-42}. Here, the larger collection of bivalent binding antibodies expands the previous Group E and F into E1-E3 and F1-F3, which respectively target the front and backside of RBD (Fig. 1b).

By projecting each antibody's experimental measurements against each sarbecovirus onto the t-distributed stochastic neighbor embedding (t-SNE) dimension, we surprisingly found that antibodies of the same cluster have unified sarbecovirus neutralization potency and binding spectra (Fig. 1c-f, Extended Data Fig. 4a-e). Moreover, the antibodies' neutralization mechanism also tends to cluster based on the epitope distribution. Antibodies of group E1-E3 and F1 do not compete with ACE2 (Fig. 1g), which results in relatively weaker neutralizing potency compared to ACE2-blocking antibody (Extended Data Fig. 5a), except that group E1 antibodies still possess high neutralization potency (Fig. 1c), suggesting a rather unique neutralization mechanism. In total, 6 clusters of antibodies were found to exhibit broad sarbecovirus neutralizing ability with diverse breadth, namely Group E1, E3, F1, F2, F3 and a subcluster of Group B (Fig 1a, 1e-f).

Group E1 antibodies display potent neutralizing activities against human infecting sarbecoviruses, including both SARS-CoV-2 variants and SARS-CoV-1 variants (Fig. 1c, Extended Data Fig. 5b). Their epitope is fully exposed regardless of the up and down conformations of RBD and may involve a mixed protein and carbohydrate, specifically the N-linked glycan on N343, as for S309¹⁹. Indeed this unique feature is shared among Group E antibodies, evidenced by structural analyses of BD55-3152, BD55-3546 and BD55-5840 in complex with spike proteins using cryo-electron microscopy (cryo-EM) (Fig. 2a, Extended Data Fig. 6a-b). Importantly, members of Group E1 are generally sensitive to the changes of G339, E340, T345 and especially R346, revealed by their escaping mutation profiles and structures (Fig. 2a, d). Thus, most E1 antibodies could not bind to clade 2 and 3 sarbecoviruses because of the changes of RBD antigenic sites corresponding to G339, E340 and R346, as calculated by multiple sequence alignment (MSA) (Fig. 1f, Fig. 2d). Importantly, Omicron causes considerable antibody escaping for Group E1 (Fig. 1d); however, a proportion of E1 antibodies that could tolerate G339D and N440K mutations could retain potent neutralizing ability against BA.1, BA.1.1, and BA.2, making them good therapeutics candidates (Extended Data Fig. 7).

Interestingly, despite the importance of R346 to E1 antibodies, the additional R346K carried by BA.1.1 does not readily affect their efficacy (Fig. 1d). This is foreseeable, as Arg and Lys possess similar chemical properties. In fact, SARS-CoV-1 features a Lys at the corresponding site (K333) (Fig. 2d). The structure of BD55-3152 in complex with the Omicron spike reveals that a CDRL2 Asp (D50) interacts with R346 (Fig. 2a), whereas the structure of BD55-3152 complexed with the SARS-CoV-1 spike shows that the same Asp also coordinates K333 (Extended Data Fig. 8). Nevertheless, most E1 antibodies lost binding and neutralization ability towards clade 1a/1b sarbecoviruses circulating among animals, including the bat coronavirus RaTG13 and the pangolin coronavirus Pangolin-GD (Fig. 1e, Extended Data Fig. 5f-g). This is largely because of the Thr substitution in these sarbecoviruses (Fig. 2d). In contrast to R346K, R346S/T would greatly compromise the binding activities of E1 antibodies.

Group E2 antibodies are directed to the front chest of RBD. Previously, we solved cryo-EM structures of several neutralizing antibodies in this group, including BD-744⁴³ (Fig. 2b). These neutralizing antibodies target a relatively flat region partially exposed in the down RBDs. The E2 antibodies are sensitive to mutations of R346, A348, A352, K356, R357, L452, and I468, and these sites are largely not conserved in clade 1a/2/3 sarbecoviruses (Fig. 2d). Therefore, the E2 Antibodies usually do not have broad sarbecovirus neutralizing ability (Fig. 1e-f, Extended Data Fig. 4a-e). The L452R mutation in the Delta variant also substantially abrogates their activities (Fig. 2d). Nonetheless, most E2 antibodies can still neutralize Omicron BA.1, since Omicron BA.1 do not have mutations at the sites mentioned above (Fig. 1d, Extended Data Fig. 5c-e); however, the R346K carried by BA.1.1 would escape E2 antibodies as well (Fig. 2d), such as Brii-198.

Group E3 antibodies, such as S2H97²⁰, bind to the left flank of RBD (Fig. 2c). As this epitope region is deeply buried within the spike trimer, the E3 antibodies can only bind when the RBD adopts a not only up but also wide open conformation. Likely because of this, the neutralizing activities of group E3 antibodies are relatively modest. Critically sites recognized by E3 antibodies include R357, T393, Y396, D428, K462, S514, E516 and L518, all well conserved in most sarbecoviruses (Fig. 2d); thus, the E3 antibodies display great neutralization breadth (Fig. 1f, Extended Data Fig. 4a-e). Interestingly, though not escaped by Omicron variants, their overall neutralizing activities are reduced (Fig. 1d). The neutralization mechanisms of S2H97 and other antibodies targeting the cryptic sites in RBD have been partly attributed to their ability to disrupt the spike trimer's prefusion state, as these antibodies demand the extensive opening of the RBD to engage their respective binding sites^{20,44-46}. Their reduced activities towards Omicron could thus be caused by the more stabilized prefusion structure of Omicron spike⁴⁷.

Group F1, F2, and F3 antibodies cover a continuous surface on the backside of RBD

and can only bind to the up RBDs (Fig. 1b). Members of the F1 group, such as CR3022²¹ and S304²², also require a wide open RBD to engage and do not directly block ACE2, therefore displaying weak neutralizing activities in general (Fig. 1c). Escape hotspots for this group include SARS-CoV-2 residues 383-386, 390, and 391 (Fig. 3a, d). Most of these sites are conserved in all sarbecoviruses, except an alanine on 384 in clade 1a, which is also tolerated (Fig. 3d). Due to their intrinsic weak neutralizing activities and the triple mutations on S371, S373, S375 of Omicron, we found that the F1 antibodies virtually have no neutralizing power against Omicron variants (Fig. 1d, Extended Data Fig. 5c-e).

The epitopes for group F2 antibodies are shifted upward compared with F1 (Fig. 3b). We solved the cryo-EM structure of two representative antibodies in this group, BD55-1239 and BD55-3500, both in complexes with the Omicron spike (Fig. 3b, Extended Data Fig. 6c). Structural analyses showed that although these antibodies do not directly target the ACE2-binding residues, both project towards where ACE2 would be lodged and therefore exclude ACE2 through steric hindrance, like DH1047²³ (Fig. 3b). Group F2 antibodies can be escaped by RBD mutation involving T376, K378, and R408 (Fig. 3d). Indeed, these residues are all at the heart of BD55-1239's and BD55-3500's epitopes. These sites are fairly conserved across sarbecoviruses (Fig. 3b, d), and the neutralization breadth of group F2 antibodies is comparable to that of E3 and F1 (Fig. 1e-f). A notable exception is the corresponding K378Q substitution in BM48-31, which might compromise the binding of many F2 antibodies (Extended Data Fig. 4d). Despite the extraordinary breadth and potency against sarbecovirus, Group F2 antibodies suffer great neutralization efficacy reduction against Omicron, mostly due to the triple mutations on S371, S373, S375 (Fig. 1d). Importantly, mutation T376A and R408S harbored by Omicron BA.2 completely abolished the neutralizing capacity of F2 antibodies (Fig. 1d, Extended Data Fig. 5e).

Group F3 Antibodies reach further towards the ACE2-binding site, such as S2X259²⁶ and ADG-2²⁴ (Fig. 1b). Cryo-EM structures of BD55-4637 complexed with the

Omicron spike and BD55-3372 with the Delta spike reveal that F3 antibodies interact with several ACE2-binding residues (Fig. 3c, Extended Data Fig. 6d), and therefore directly compete with ACE2. Major escape sites for this group of antibodies include D405, R408, V503, G504, and Y508 (Fig. 3d). Given the fact that D405, G504, and Y508 are not conserved in clade 2 sarbecoviruses, F3 antibodies cannot bind to non-ACE2 utilizing clade 2 sarbecovirus (Extended Data Fig. 4e), but showed good neutralization breadth against clade 1a/b/2 sarbecovirus (Fig. 1e-f). Similar to Group E1, a proportion of F3 antibodies showed potent neutralization against Omicron BA.1, despite the Y505H mutation carried by Omicron (Fig. 1d, 3d). Moreover, several elite members of BA.1 tolerating F3 antibodies could also overcome the D405N and R408S mutations of BA.2, making them good therapeutic drug candidates (Fig 1d, Extended Data Fig. 7).

Notably, a unique subcluster of Group B antibodies also showed broad-spectrum sarbecovirus neutralizing capability (Fig 1c). Most Group B antibodies are SARS-CoV-2 specific since their major escaping mutations consist of E484 and F486, which are not conserved in sarbecovirus clade (Extended Data Fig. 9); however, the rare subcluster B', featured by S2K146²⁵, displayed skewed escaping mutation profiles toward N487 and Y489, which are highly conserved in clade 1a/1b/3 (Extended Data Fig. 9), making members of B' exhibits similar breadth as F3 antibodies. Sadly, most B' antibodies failed to neutralize Omicron, except for S2K146⁶ (Fig. 1d).

The above analyses indicate that each epitope group's mutational escape hotspots are closely related to the antibodies' sarbecovirus reactivity breadth. To further extrapolate this observation, we simulated each antibody's sarbecovirus RBD binding spectrum based on its escaping mutation profile and the corresponding MSA results of sarbecovirus RBDs (Extended Data Fig. 10a-e). Surprisingly, the simulated spectrum well matches that obtained from ELISA (Extended Data Fig. 4a-e), suggesting that the antibody's breadth is mostly governed by the degree of conservation of its major mutational escaping sites, and the escaping mutation profile of an antibody could be

used to predict its sarbecovirus binding spectrum.

Importantly, even broad sarbecovirus neutralizing antibodies are largely escaped by Omicron (Fig. 1b), which is consistent with that Omicron could greatly reduce the neutralization efficacy of vaccinated SARS convalescents' plasma (Extended Data Fig. 1c). This supports the speculation that Omicron does not originate from zoonotic spillover but immune selection pressure. Indeed, multiple top antibody-escaping mutations inferred from yeast display have appeared on Omicron variants, including K417N, E484A, Q490R, G446S, G339D, R346K, N440K, T376A, D405N and R408S (Supplementary Data 3). Especially BA.2, which has evolved multiple mutations on the sarbecovirus conserved amino acids (D405N, R408S and T376A) that could cause pinpoint escapes of most F2 and partial F3 broad-spectrum neutralizing antibodies (Fig. 1d, Extended Data Fig. 3). Nevertheless, BA.2 lacks the G446S mutation, and thus part of group D antibodies that target the linear 440-449 loop retained their neutralization capability against BA.2, such as REGEN-1098748 and AZD106149 (Fig. 1d).

We have identified a large panel of potent sarbecovirus neutralizing antibodies that stay effective to Omicron variants, mainly belonging to Group E1, F2 and F3. To further examine their potential as antibody therapeutics, we analyzed these antibodies' authentic virus neutralization potency against Omicron (BA.1) as well as their binding affinity against sarbecovirus RBDs, along with well-recognized broad-spectrum neutralizing antibody serving as controls (Fig. 4a, Supplementary Data 4). Several antibodies, such as BD55-5840 (E1), BD55-3546 (E1), BD55-5640 (F2), BD55-5514 (F3) and BD55-5483 (F3), stand out as promising drug candidates (Fig. 4a).

In addition, pairing non-competing antibodies into cocktails is a promising strategy to reduce the chance of mutation-induced antibody evasion. As the epitopes of the E1 antibodies are located on the opposite sides of RBD compared to F2 and F3, we envision that many E1 antibodies can function in combinations with an F2 or F3 counterpart. Indeed, several plausible strategies can be designed based on the structural

information presented in this study. For example, overlaying the targeting RBDs in the BD55-5840 (E1) and BD55-3500 (F2) cryo-EM structures demonstrate that they can readily bind to the Omicron RBD simultaneously (Fig. 4b), whereas BD55-3546 (E1) can bind concurrently with BD55-3372 (F3) on the Delta RBD (Fig. 4c). From a mechanistic point of view, E1 antibodies do not directly impede ACE2 but can engage both the up and down RBDs, whereas F2/F3 antibodies only bind to the up RBDs but promptly blocks ACE2. Due to these complementary properties, they might synergize in an ideal way to achieve maximized breadth and potency.

Our results could also guide the development of broad sarbecovirus vaccines. According to our analyses, certain neutralizing antibodies, such as those belonging to E1, F2, F3 epitope groups, should be the ideal inducing targets of broad sarbecovirus vaccines, since their neutralization potency and breadth far exceeds the antibodies in other epitope groups. Also, the overall mean escaping mutation profile for each epitope group has great implications for rational vaccine antigen design (Supplementary Data 3). It could offer the exact mutation combination that should be used to avoid stimulating a certain antibody group, such as a vaccine booster dose using a spike protein with K417D/F456K/A475R mutations should completely block the stimulation of Group A antibodies. Together, our results provide a comprehensive understanding of the RBD epitopes that can induce broad sarbecovirus neutralizing antibodies, which offers critical instructions for sarbecovirus antibody therapeutics and the antigen design of broad-spectrum sarbecovirus vaccines.

Reference

- 1 Viana, R. *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*, doi:10.1038/s41586-022-04411-y (2022).
- 2 Lu, L. *et al.* Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. *Clin Infect Dis*, doi:10.1093/cid/ciab1041 (2021).
- 3 Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature*, doi:10.1038/s41586-021-04387-1 (2021).
- 4 Collie, S., Champion, J., Moultrie, H., Bekker, L. G. & Gray, G. Effectiveness of BNT162b2 Vaccine

298 against Omicron Variant in South Africa. *N Engl J Med* **386**, 494-496,
299 doi:10.1056/NEJMc2119270 (2022).

300 5 Dejnirattisai, W. *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from
301 neutralizing antibody responses. *Cell*, doi:10.1016/j.cell.2021.12.046 (2022).

302 6 Cameroni, E. *et al.* Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic
303 shift. *Nature*, doi:10.1038/s41586-021-04386-2 (2021).

304 7 Cao, Y. *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
305 *Nature*, doi:10.1038/s41586-021-04385-3 (2021).

306 8 Liu, L. *et al.* Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2.
307 *Nature*, doi:10.1038/s41586-021-04388-0 (2021).

308 9 Planas, D. *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature*,
309 doi:10.1038/s41586-021-04389-z (2021).

310 10 Lyngse, F. P. *et al.* Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2:
311 Evidence from Danish Households. *medRxiv* (2022).

312 11 Corti, D., Purcell, L. A., Snell, G. & Veessler, D. Tackling COVID-19 with neutralizing monoclonal
313 antibodies. *Cell* **184**, 3086-3108, doi:10.1016/j.cell.2021.05.005 (2021).

314 12 Cohen, A. A. *et al.* Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic
315 coronaviruses in mice. *Science* **371**, 735-741, doi:10.1126/science.abf6840 (2021).

316 13 Martinez, D. R. *et al.* Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in
317 mice. *Science* **373**, 991-998, doi:10.1126/science.abi4506 (2021).

318 14 Walls, A. C. *et al.* Elicitation of broadly protective sarbecovirus immunity by receptor-binding
319 domain nanoparticle vaccines. *Cell* **184**, 5432-5447 e5416, doi:10.1016/j.cell.2021.09.015
320 (2021).

321 15 Starr, T. N. *et al.* Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals
322 Constraints on Folding and ACE2 Binding. *Cell* **182**, 1295-1310 e1220,
323 doi:10.1016/j.cell.2020.08.012 (2020).

324 16 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding
325 domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* **29**,
326 463-476 e466, doi:10.1016/j.chom.2021.02.003 (2021).

327 17 Greaney, A. J. *et al.* Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding
328 Domain that Escape Antibody Recognition. *Cell Host Microbe* **29**, 44-57 e49,
329 doi:10.1016/j.chom.2020.11.007 (2021).

330 18 Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD
331 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
332 *Cell Rep Med* **2**, 100255, doi:10.1016/j.xcrm.2021.100255 (2021).

333 19 Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
334 *Nature* **583**, 290-295, doi:10.1038/s41586-020-2349-y (2020).

335 20 Starr, T. N. *et al.* SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
336 *Nature* **597**, 97-102, doi:10.1038/s41586-021-03807-6 (2021).

337 21 Yuan, M. *et al.* A highly conserved cryptic epitope in the receptor binding domains of SARS-
338 CoV-2 and SARS-CoV. *Science* **368**, 630-633, doi:10.1126/science.abb7269 (2020).

339 22 Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
340 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024-1042
341 e1021, doi:10.1016/j.cell.2020.09.037 (2020).

342 23 Martinez, D. R. *et al.* A broadly cross-reactive antibody neutralizes and protects against
343 sarbecovirus challenge in mice. *Sci Transl Med* **14**, eabj7125,
344 doi:10.1126/scitranslmed.abj7125 (2022).

345 24 Rappazzo, C. G. *et al.* Broad and potent activity against SARS-like viruses by an engineered
346 human monoclonal antibody. *Science* **371**, 823-829, doi:10.1126/science.abf4830 (2021).

347 25 Park, Y. J. *et al.* Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular
348 mimicry. *Science* **375**, 449-454, doi:10.1126/science.abm8143 (2022).

349 26 Tortorici, M. A. *et al.* Broad sarbecovirus neutralization by a human monoclonal antibody.
350 *Nature* **597**, 103-108, doi:10.1038/s41586-021-03817-4 (2021).

351 27 Lv, H. *et al.* Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
352 *Cell Rep* **31**, 107725, doi:10.1016/j.celrep.2020.107725 (2020).

353 28 Jette, C. A. *et al.* Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-
354 19 donor-derived neutralizing antibodies. *Cell Rep* **36**, 109760,
355 doi:10.1016/j.celrep.2021.109760 (2021).

356 29 Liu, H. *et al.* A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2
357 and SARS-CoV pseudovirus infection. *Cell Host Microbe* **29**, 806-818 e806,
358 doi:10.1016/j.chom.2021.04.005 (2021).

359 30 Wec, A. Z. *et al.* Broad neutralization of SARS-related viruses by human monoclonal antibodies.
360 *Science* **369**, 731-736, doi:10.1126/science.abc7424 (2020).

361 31 Burnett, D. L. *et al.* Immunizations with diverse sarbecovirus receptor-binding domains elicit
362 SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. *Immunity* **54**,
363 2908-2921 e2906, doi:10.1016/j.immuni.2021.10.019 (2021).

364 32 Wang, P. *et al.* A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and
365 other sarbecoviruses. *Emerg Microbes Infect* **11**, 147-157,
366 doi:10.1080/22221751.2021.2011623 (2022).

367 33 Vanshylla, K. *et al.* Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2
368 elite neutralizers. *Cell Host Microbe* **30**, 69-82 e10, doi:10.1016/j.chom.2021.12.010 (2022).

369 34 Onodera, T. *et al.* A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and
370 variants by coordinated recognition of a virus-vulnerable site. *Immunity* **54**, 2385-2398 e2310,
371 doi:10.1016/j.immuni.2021.08.025 (2021).

372 35 Tan, C. W. *et al.* Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-
373 1 Survivors. *N Engl J Med* **385**, 1401-1406, doi:10.1056/NEJMoa2108453 (2021).

374 36 Cao, Y. *et al.* Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput
375 Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **182**, 73-84 e16,
376 doi:10.1016/j.cell.2020.05.025 (2020).

377 37 Scheid, J. F. *et al.* B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-
378 CoV. *Cell* **184**, 3205-3221 e3224, doi:10.1016/j.cell.2021.04.032 (2021).

379 38 Cao, Y. *et al.* Humoral immune response to circulating SARS-CoV-2 variants elicited by
380 inactivated and RBD-subunit vaccines. *Cell Res* **31**, 732-741, doi:10.1038/s41422-021-00514-9
381 (2021).

382 39 Greaney, A. J. *et al.* Mapping mutations to the SARS-CoV-2 RBD that escape binding by different
383 classes of antibodies. *Nat Commun* **12**, 4196, doi:10.1038/s41467-021-24435-8 (2021).

384 40 Dejnirattisai, W. *et al.* The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell* **184**,
385 2183-2200 e2122, doi:10.1016/j.cell.2021.02.032 (2021).

386 41 Barnes, C. O. *et al.* SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
387 *Nature* **588**, 682-687, doi:10.1038/s41586-020-2852-1 (2020).
388 42 Yuan, M. *et al.* Structural and functional ramifications of antigenic drift in recent SARS-CoV-2
389 variants. *Science* **373**, 818-823, doi:10.1126/science.abh1139 (2021).
390 43 Du, S. *et al.* Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into
391 cocktail design against concerning variants. *Cell Res* **31**, 1130-1133, doi:10.1038/s41422-021-
392 00555-0 (2021).
393 44 Li, T. *et al.* Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating
394 variants. *Nat Commun* **12**, 5652, doi:10.1038/s41467-021-25997-3 (2021).
395 45 Huo, J. *et al.* Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host*
396 *Microbe* **28**, 445-454 e446, doi:10.1016/j.chom.2020.06.010 (2020).
397 46 Wrobel, A. G. *et al.* Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. *Nat*
398 *Commun* **11**, 5337, doi:10.1038/s41467-020-19146-5 (2020).
399 47 Cui, Z. *et al.* Structural and functional characterizations of infectivity and immune evasion of
400 SARS-CoV-2 Omicron. *Cell*, doi:10.1016/j.cell.2022.01.019.
401 48 Hansen, J. *et al.* Studies in humanized mice and convalescent humans yield a SARS-CoV-2
402 antibody cocktail. *Science* **369**, 1010-1014, doi:10.1126/science.abd0827 (2020).
403 49 Dong, J. *et al.* Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-
404 antibody cocktail. *Nat Microbiol* **6**, 1233-1244, doi:10.1038/s41564-021-00972-2 (2021).
405
406

408 **Methods**

409 **Antibody isolation and recombinant production**

410 SARS-CoV-1 and SARS-CoV-2 RBD cross-binding memory B cells were isolated from
411 PBMC of SARS-CoV-1 convalescents who received SARS-CoV-2 vaccine. Briefly,
412 CD19⁺ B cells were isolated from PBMC with EasySep™ Human CD19 Positive
413 Selection Kit II (STEMCELL, 17854). B cells were then stained with FITC anti-human
414 CD19 antibody (BioLegend, 392508), FITC anti-human CD20 antibody (BioLegend,
415 302304), Brilliant Violet 421™ anti-human CD27 antibody (BioLegend, 302824),
416 PE/Cyanine7 anti-human IgM antibody (BioLegend, 314532), biotinylated Ovalbumin
417 (SinoBiological) conjugated with Brilliant Violet 605™ Streptavidin (BioLegend,
418 405229), SARS-CoV-1 biotinylated RBD protein (His & AVI Tag) (SinoBiological,
419 40634-V27H-B) conjugated with PE-streptavidin (BioLegend, 405204), SARS-CoV-2
420 biotinylated RBD protein (His & AVI Tag) (SinoBiological, 40592-V27H-B)

conjugated with APC-streptavidin (BioLegend, 405207), and 7-AAD (Invitrogen, 00-6993-50). CD19/CD20⁺, CD27⁺, IgM⁻, OVA⁻, SARS-COV-1 RBD⁺, and SARS-CoV-2 RBD⁺ were sorted with MoFlo Astrios EQ Cell Sorter (Beckman Coulter). FACS data were analyzed using FlowJo™ v10.8 (BD Biosciences).

Sorted SARS-CoV-1 and SARS-CoV-2 RBD cross-binding B cells were then processed with Chromium Next GEM Single Cell V(D)J Reagent Kits v1.1 following the manufacturer's user guide (10x Genomics, CG000208). Briefly, Cells sorted were resuspend in PBS after centrifugation. Gel beads-in-emulsion (GEMs) were obtained with 10X Chromium controller and then subjected to reverse transcription (RT). After GEM-RT clean up, RT products were subject to preamplification. After amplification and purification with SPRIselect Reagent Kit (Beckman Coulter, B23318) of RT products, B cell receptor (BCR) sequence (paired V(D)J) were enriched with 10X BCR primers. After library preparation, libraries were sequenced by Novaseq 6000 platform running Novaseq 6000 S4 Reagent Kit v1.5 300 cycles (Illumina, 20028312) or NovaSeq XP 4-Lane Kit v1.5 (Illumina, 20043131).

After sequencing and data processing, monoclonal antibodies were expressed as recombinant human IgG1. Briefly, HEK293F cells (Thermo Fisher, R79007) were transiently transfected with heavy and light chain expression vectors. The secreted monoclonal antibodies from cultured cells were purified by protein A affinity chromatography. The specificities of these antibodies were determined by ELISA.

Antibody sequence analysis

The antibody sequences obtained from 10X Genomics V(D)J sequencing were aligned to GRCh38 reference and assembled as immunoglobulin contigs by the Cell Ranger (v6.1.1) pipeline. Non-productive contigs and B cells that had multiple heavy chain or light chain contigs were filtered out of the analysis. V(D)J gene annotation was performed using NCBI IgBlast (v1.17.1) with the IMGT reference. Mutations on V(D)J nucleotide sequences were calculated by using the igpipeline, which compared the

sequences to the closest germline genes and counted the number of different nucleotides. For antibodies from public sources whose original sequencing nucleotide sequences were not all accessible, the antibody amino acid sequences were annotated by IMGT/DomainGapAlign⁵⁰ (v4.10.2) with default parameters. The V-J pairs were visualized by R package circlize (v0.4.10).

High-throughput antibody-escape mutation profiling

The previously described high-throughput MACS (magnetic-activated cell sorting)-based antibody-escape mutation profiling system was used to characterize RBD escaping mutation profile for neutralizing antibodies. Briefly, duplicate RBD mutant libraries were constructed based on Wuhan-Hu-1 RBD sequence (GenBank: MN908947, residues N331-T531), theoretically containing 3819 possible amino acid mutations. Each RBD mutant was barcoded with a unique 26-nucleotide (N26) and only ACE2 binding variants were enriched for downstream experiment.

For antibody escape profiling, yeast libraries were induced overnight for RBD expression and washed followed by two rounds of Protein A antibody based negative selection and MYC-tag based positive selection to enrich RBD expressing cells. Protein A antibody conjugated products were prepared following the protocol of Dynabeads Protein A (Thermo Fisher, 10008D) and incubated with induced yeast libraries at room temperature. MYC-tag based positive selection was performed according to the manufacturer's protocol (Thermo Fisher, 88843).

After three rounds of sequential cell sorting, the obtained yeast cells were recovered overnight. Plasmids were extracted from pre- and post-sort yeast populations by 96-Well Plate Yeast Plasmid Preps Kit (Coolaber, PE053). The extracted plasmids were then used to amplify N26 barcode sequences by PCR. The final PCR products were purified with AMPure XP magnetic beads (Beckman Coulter, A63882) and 75bp single-end sequencing was performed on an Illumina Nextseq 500 platform.

Processing of deep mutational scanning data

Single-end Illumina sequencing reads were processed as previously described. Briefly, reads were trimmed into 16 or 26 bp and aligned to the reference barcode-variant dictionary with `dms_variants` package (v0.8.9). Escape scores of variants were calculated as $F \times (n_{X,ab} / N_{ab}) / (n_{X,ref} / N_{ref})$, where $n_{X,ab}$ and $n_{X,ref}$ is the number of reads representing variant X, and N_{ab} and N_{ref} are the total number of valid reads in antibody-selected (ab) and reference (ref) library, respectively. F is a scale factor defined as the 99th percentiles of escape fraction ratios. Variants detected by less than 6 reads in the reference library were removed to avoid sampling noise. Variants containing mutations with ACE2 binding below -2.35 or RBD expression below -1 were removed as well, according to data previously reported. Finally, global epistasis models were built using `dms_variants` package to estimate mutation escape scores. For most antibodies, at least two independent assays are conducted and single mutation escape scores are averaged across all experiments that pass quality control.

Antibody clustering and visualization

Site total escape scores, defined as the sum of escape scores of all mutations at a particular site on RBD, were used to evaluate the impact of mutations on each site for each antibody. Each of these scores is considered as a feature of a certain antibody and used to construct a feature matrix $A_{N \times M}$ for downstream analysis, where N is the number of antibodies and M is the number of features (valid sites). Informative sites were selected using `sklearn.feature_selection.VarianceThreshold` of scikit-learn Python package (v0.24.2) with the variance threshold as 0.1. Then, the selected features were L2-normalized across antibodies using `sklearn.preprocessing.normalize`. The resulting matrix is referred as $A'_{N \times M'}$, where M' is the number of selected features. The dissimilarity of two antibodies i, j is defined as $1 - \text{Corr}(A'_i, A'_j)$, where $\text{Corr}(x, y)$ is the Pearson's correlation coefficient of vector x and y, i.e. $\text{Corr}(x, y) = \frac{x \cdot y}{|x||y|}$. We used `sklearn.manifold.MDS` to reduce the number of features from M' to D=20 with multidimensional scaling under the above metric. Antibodies are clustered into 10 epitope groups using `sklearn.cluster.KMeans` of scikit-learn in the resulting D-

dimensional feature space. Finally, these D-dimensional representations of antibodies were further embedded into two-dimensional space for visualization with t-SNE using sklearn.manifold.TSNE of scikit-learn. All t-SNE plots were generated by R package ggplot2 (v3.3.3).

Pseudovirus neutralization assay

SARS-CoV-2 spike (GenBank: MN908947), Pangolin-GD spike (GISAID: EPI_ISL_410721), RaTG13 spike (GISAID: EPI_ISL_402131), SARS-COV-1 spike (GenBank: AY278491), Omicron BA.1 spike (A67V, H69del, V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F), BA.2 spike (GISAID: EPI_ISL_7580387), BA.1.1 spike (BA.1+R346K), plasmid is constructed into pcDNA3.1 vector. G*ΔG-VSV virus (VSV G pseudotyped virus, Kerafast) is used to infect 293T cells (American Type Culture Collection [ATCC], CRL-3216), and spike protein expressing plasmid was used for transfection at the same time. After culture, the supernatant containing pseudovirus was harvested, filtered, aliquoted, and frozen at −80°C for further use.

Pseudovirus detection of PCoV-GD and RaTG13 was performed in 293T cells overexpressing human angiotensin-converting enzyme 2 (293T-hACE2 cells). Other pseudovirus neutralization assays were performed using the Huh-7 cell line (Japanese Collection of Research Bioresources [JCRB], 0403).

Monoclonal antibodies or plasma were serially diluted (5-fold or 3-fold) in DMEM (Hyclone, SH30243.01) and mixed with pseudovirus in 96-well plates. After incubation at 5% CO₂ and 37°C for 1 h, digested Huh-7 cell (Japanese Collection of Research Bioresources [JCRB], 0403) or 293T-hACE2 cells (AmericanTypeCultureCollection[ATCC],CRL-3216) were seeded. After 24 hours of culture, supernatant was discarded and D-luciferin reagent (PerkinElmer, 6066769) was

added to react in the dark, and the luminescence value was detected using a microplate spectrophotometer (PerkinElmer, HH3400). IC50 was determined by a four-parameter logistic regression model.

Authentic virus neutralization

SARS-CoV-2 and SARS-CoV-2 variants neutralization by plasma were performed using cytopathic effect (CPE) assay. Plasma samples were inactivated at 56°C for 0.5h. Plasma samples were serially diluted (2 fold) in the 96-well plates with cell culture medium and mixed with 100TCID50 virus, and then incubated at 37°C, 5% CO₂ for 2 hours. About 10⁴ digested Vero cells (ATCC, CCL-81) were seeded in plates and cultured for 5 days. CPE of each well was recorded under microscopes. Assays for each sample were replicated and the neutralization titer was calculated by the Spearman-Kärber method. All experiments were performed in a Biosafety Level 3 laboratory.

ELISA

To detect the broad-spectrum binding of the antibodies among Sarbecovirus, we entrusted SinoBiological Technology Co., Ltd. to synthesize a panel of 20 sarbecovirus RBDs (Supplementary Table 3). According to the sequence of 20 RBDs, a set of nested primers was designed. The coding sequences were obtained by the overlap-PCR with a 6xHis tag sequence to facilitate protein purification. The purified PCR products were ligated to the secretory expression vector pCMV3 with CMV promoter, and then transformed into E. coli competent cells XL1-blue. Monoclones with correct transformation were cultured and expanded, and plasmids were extracted. Healthy HEK293 cells were passaged into a new cell culture and grown in suspension at 37 °C, 120 RPM, 8% CO₂ to logarithmic growth phase and transfected with the recombinant constructs by using liposomal vesicles as DNA carrier. After transfection, the cell cultures were followed to assess the kinetics of cell growth and viability for 7 days. The cell expression supernatant was collected, and after centrifugation, passed through a Ni column for affinity purification. The molecular size and purity of eluted protein was confirmed by SDS-PAGE. Production lot numbers and concentration information

of the 20 Sarbecovirus proteins are shown in Supplemenatary Table 4. The WT RBD in the article is SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein (SinoBiological, 40592-V08H).

A panel of 21 sarbecovirus RBDs (supplementary table3) in PBS was pre-coated onto ELISA Plates (NEST, 514201) at 4°C overnight. The plates were washed and blocked. Then 1µg/ml purified antibodies or serially diluted antibodies were added and incubated at room temperature (RT) for 20min. Next, Peroxidase-conjugated AffiniPure Goat Anti-Human IgG (H+L) (JACKSON, 109-035-003) was applied and incubated at RT for 15min. Tetramethylbenzidine (TMB) (Solarbio, 54827-17-7) was added onto the plates. The reaction was terminated by 2 M H₂SO₄ after 10min incubation. Absorbance was measured at 450 nm using Ensign Multimode Plate Reader (PerkinElmer, HH3400). ELISA OD450 measurements at different antibody concentration for a particular antibody-antigen pair are fit to the model $y = \frac{Ac^n}{c^n + E^n}$ using R package mosaic (v1.8.3), where y is OD450 values and c is corresponding antibody concentration. A, E, n are parameters, where E is the desired EC₅₀ value for the specific antibody and antigen.

Antibody-ACE2 competition for RBD

mFC-WT-RBD (Sino Biological, 40592-V05H) protein in PBS was immobilized on the ELISA plates at 4°C overnight. The coating solution was removed and washed three times by PBST and the plates were then blocked for 2 h. After blocking, the plates were washed five times, and the mixture of ACE2-his (Sino Biological, 10108-105H) and serially diluted competitor antibodies was added followed by 30min incubation at RT. Then anti-his-HRP (Proteintech, HRP-66005) was added into each well for another 20min incubation at RT. After washing the plates for five times, Tetramethylbenzidine (TMB) (Solarbio, 54827-17-7) was added into each well. After 10 min, the reaction was terminated by 2M H₂SO₄. Absorbance was measured at 450 nm using Ensign Multimode Plate Reader (PerkinElmer, HH3400). The ACE2 competition coefficient is calculated as (B-A)/B, where B is the OD450 value under

0.15ug/ml antibody concentration and A is the OD450 value under 3ug/ml antibody concentration.

Biolayer Interferometry

Biolayer interferometry assays were performed on Octet® RED96 Protein Analysis System (Fortebio) according to the manufacturer's instruction. The kinetics assays were conducted with protein A biosensor (ForteBio 18-5010). (1) Sensor check: sensors immersed 10 min in buffer alone (buffer ForteBio 18-1105). (2) Baseline: sensors immersed 30 s in buffer alone. (3) Loading: sensors immersed 300 s with antibody at 2 µg/ml to capture Ab, with a threshold of 0.4 nm. (4) Baseline 2: sensors immersed 120 s in buffer alone. (5) Antigen association: sensors immersed 60 s with serial dilutions of RBD or its variants at 75-5 nM. (6) Antigen dissociation: sensors immersed 600 s in buffer alone. (7) Sensor regeneration: sensors immersed 30 s in regeneration buffer (10 mM Glycine-HCl, pH 1.5), then immersed 30 s in buffer. Repeat for 2 more times. Data were collected with Octet Acquisition 9.0 (Fortebio) and analyzed by Octet Analysis 9.0 (Fortebio) and Octet Analysis Studio 12.2 (Fortebio).

Protein expression and purification for cryo-EM study

The S6P expression construct encoding the SARS-CoV-2 spike ectodomain (residues 1-1208) with six stabilizing Pro substitutions (F817P, A892P, A899P, A942P, K986P, and V987P) and a "GSAS" substitution for the furin cleavage site (residues 682–685) was previously described⁵¹. The Delta specific mutations (T19R, G142D, 156del, 157del, R158G, L452R, T478K, D614G, P681R, D950N) were introduced into this construct using site-directed mutagenesis. The S6P expression construct containing the Omicron mutations (A67V, H69del, V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G,

H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) were assembled from three synthesized DNA fragments. The expression construct encoding the SARS-CoV spike ectodomain (residues 1-1195)⁵² was kindly provided by Prof. X. Wang (Tsinghua university), and two stabilizing Pro substitutions (K968P, V969P) was engineered into this construct using mutagenesis. For protein production, these expression plasmids, as well as the plasmids encoding the antigen-binding fragments (Fabs) of the antibodies described in this paper, were transfected into the HEK293F cells using polyethylenimine (Polysciences). The conditioned media were harvested and concentrated using a Hydrosart ultrafilter (Sartorius), and exchanged into the binding buffer (25 mM Tris, pH 8.0, and 200 mM NaCl). Protein purifications were performed using the Ni-NTA affinity method, followed by gel filtration chromatographies using either a Superose 6 increase column (for the spike proteins) or a Superose 200 increase column (for the Fabs). The final buffer used for all proteins is 20 mM HEPES, pH 7.2, and 150 mM NaCl.

Cryo-EM data collection, processing, and structure building

The samples for cryo-EM study were prepared essentially as previously described^{51,53}. All EM grids were evacuated for 2 min and glow-discharged for 30 s using a plasma cleaner (Harrick PDC-32G-2). Four microliters of spike protein (0.8 mg/mL) was mixed with the same volume of Fabs (1 mg/mL each), and the mixture was immediately applied to glow-discharged holy-carbon gold grids (Quantifoil, R1.2/1.3) in an FEI Vitrobot IV (4 °C and 100% humidity). Data collection was performed using either a Titan Krios G3 equipped with a K3 direct detection camera, or a Titan Krios G2 with a K2 camera, both operating at 300 kV. Data processing was carried out using cryoSPARC⁵⁴. After 2D classification, particles with good qualities were selected for global 3D reconstruction and then subjected to homogeneous refinement. To improve the density surrounding the RBD-Fab region, UCSF Chimera⁵⁵ and Relion⁵⁶ were used to generate the masks, and local refinement was then performed using cryoSPARC. Coot⁵⁷ and Phenix⁵⁸ were used for structural modeling and refinement. Figures were prepared using UCSF ChimeraX⁵⁹ and Pymol (Schrödinger, LLC.).

Reference

- 50 Ehrenmann, F. & Lefranc, M. P. IMGT/DomainGapAlign: IMGT standardized analysis of amino acid sequences of variable, constant, and groove domains (IG, TR, MH, IgSF, MhSF). *Cold Spring Harb Protoc* **2011**, 737-749, doi:10.1101/pdb.prot5636 (2011).
- 51 Du, S. *et al.* Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. *Cell* **183**, 1013-1023 e1013, doi:10.1016/j.cell.2020.09.035 (2020).
- 52 Gui, M. *et al.* Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. *Cell Res* **27**, 119-129, doi:10.1038/cr.2016.152 (2017).
- 53 Du, S. *et al.* Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. *Cell research*, doi:10.1038/s41422-021-00555-0 (2021).
- 54 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods* **14**, 290-296, doi:10.1038/nmeth.4169 (2017).
- 55 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-1612, doi:10.1002/jcc.20084 (2004).
- 56 Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* **7**, doi:10.7554/eLife.42166 (2018).
- 57 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486-501, doi:10.1107/S0907444910007493 (2010).
- 58 Liebschner, D. *et al.* Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* **75**, 861-877, doi:10.1107/S2059798319011471 (2019).
- 59 Pettersen, E. F. *et al.* UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci* **30**, 70-82, doi:10.1002/pro.3943 (2021).

Declaration of interests

X.S.X. and Y.C. are listed as inventors on the provisional patent applications of BD series antibodies. X.S.X. and Y.C. are founders of Singlomics Biopharmaceuticals. The remaining authors declare no competing interests.

Corresponding authors

Correspondence to Yunlong Cao or Ronghua Jin or Junyu Xiao or Xiaoliang Sunney Xie. Request for materials described in this study should be directed to Yunlong Cao and Xiaoliang Sunney Xie.

Data availability

Logo plots of escape maps for antibodies in this study are available in Supplementary Data 1. Processed mutation escape scores can be downloaded at <https://github.com/jianfcphu/SARS-CoV-2-RBD-DMS-broad>. Raw Illumina and PacBio sequencing data are available on NCBI Sequence Read Archive BioProject PRJNA787091. We used vdj_GRCh38_alts_ensembl-5.0.0 as the reference of V(D)J alignment, which can be obtained from <https://support.10xgenomics.com/single-cell-vdj/software/downloads/latest>. IMGT/DomainGapAlign is based on the built-in latest IMGT antibody database, and we let the "Species" parameter as "Homo sapiens" while kept the others as default. Public deep mutational scanning datasets involved in the study from literature could be downloaded at https://media.githubusercontent.com/media/jbloomlab/SARS2_RBD_Ab_escape_map_s/main/processed_data/escape_data.csv.

Code availability

Codes for analyzing SARS-CoV-2 escaping mutation profile data are available at <https://github.com/sunneyxielab/SARS-CoV-2-RBD-Abs-HTDMS>. R and Python scripts for reproducing figures in this manuscript are available at <https://github.com/jianfcphu/SARS-CoV-2-RBD-DMS-broad>.

Fig. 1 | Comprehensive epitope and functional mapping of broad sarbecovirus neutralizing antibodies.

a, t-distributed stochastic neighbor embedding (t-SNE) and unsupervised k-means clustering of neutralizing antibodies against SARS-CoV-2 based on antibody escape maps characterized by MACS-based high-throughput deep mutational screening. **b**, Representative antibody structures of ten epitope groups. **c-e**, Neutralization of sarbecovirus (spike-pseudotyped VSV) by 715 RBD antibodies. Color bars indicate IC50 values ($\mu\text{g/mL}$). **c**, SARS-CoV-2 D614G and SARS-CoV-1 HKU-39849. **d**, Omicron variants BA.1, BA.1.1 and BA.2. **e**, SARS-CoV-2 related sarbecovirus Pangolin-GD and RaTG13. **f**, ELISA reactivity to various sarbecovirus RBD of different clades of 715 RBD antibodies. ELISA OD450 is measured using 0.3 $\mu\text{g/mL}$ antigen and 1 $\mu\text{g/mL}$ antibody. Shades of red show the average OD450 of BM48-31 and BtKY72 (for clade 3, left), and the average of YN2013, Shaanxi2011, SC2018, Rp3, ZXC21, ZC45 and Anlong112 (for clade 2, right). **g**, The ACE2 blocking activity for 715 RBD antibodies. Shades of blue show the competition level measured through competing ELISA. All pseudovirus neutralization assays and ELISA measure-

Fig. 2 | Structural and escaping mutation analyses of group E1-E3 antibodies.

a-c, High-resolution cryo-electron microscopy antibody structures of representative epitope group E1-E3 neutralizing antibodies. **a**, BD55-3152 (group E1) in complex of SARS-CoV-2 Omicron RBD complex. **b**, BD-744 (group E2) in complex of SARS-CoV-2 Beta RBD complex (PDB: 7EY0). **c**, S2H97 (group E3) in complex of SARS-CoV-2 RBD complex (PDB: 7M7W). Residues on the binding interface are marked. Residues highlighted in red indicate featuring escaping hotspots of the representative epitope groups. **d**, Averaged escape maps of antibodies in epitope group E1-E3, and corresponding multiple sequence alignment (MSA) of various sarbecovirus RBDs. Height of each amino acid in the escape maps represents its mutation escape score. Residues are colored corresponding to their chemical properties. Mutated sites in Omicron variants are marked in bold.

Fig. 3 | Structural and escaping mutation analyses of group F1-F3 antibodies.

a-c, High-resolution cryo-electron microscopy antibody structures of representative epitope group F1-F3 neutralizing antibodies. **a**, S304 (group F1) in complex of SARS-CoV-2 RBD complex (PDB: 7JW0). **b**, BD55-1239 (group F2) in complex of SARS-CoV-2 Omicron RBD complex. **c**, BD55-4637 (group F3) in complex of SARS-CoV-2 Omicron RBD complex. Residues on the binding interface are marked. Residues highlighted in red indicate featuring escaping hotspots of the representative epitope groups. **d**, Averaged escape maps of antibodies in epitope group F1-F3, and corresponding multiple sequence alignment (MSA) of various sarbecovirus RBDs. Height of each amino acid in the escape maps represents its mutation escape score. Residues are colored corresponding to their chemical properties. Mutated sites in Omicron variants are marked in bold.

a

Antibody		S309	BD55-5840	BD55-3546	BD55-5549	BD55-5585	S2H97	BD55-5263	BD55-5640	BD55-5242	BD55-3500	BD55-5700	S2X259	BD55-3372	BD55-5514	BD55-5483	BD55-5558	ADG-2	
Epitope Group		E1	E1	E1	E1	E1	E3	E3	F2	F2	F2	F2	F3	F3	F3	F3	F3	F3	
IC50 (ng/mL)	Pseudovirus	D614G	78.3	0.9	1.1	1.1	2.1	571.7	244.2	14.3	15.4	105.3	73.3	125.2	6.8	10.7	13.8	15.7	13.4
		SARS-CoV-1	31.3	5.6	4.6	24.3	6.5	6743.2	51.1	14.3	4.4	52.2	10.5	46.2	13.8	4.4	5.8	4.0	1.7
		BA.1	355.7	4.4	5.8	26.5	13.2	2407.6	1785.4	69.2	25.3	578.2	66.9	1847.0	20.3	1.7	6.5	16.0	1467.0
		BA.1.1	314.0	4.5	3.5	14.1	4.8	2231.2	1922.4	79.3	44.5	1218.8	92.7	2341.2	14.0	3.0	5.2	12.5	990.6
		BA.2	944.4	16.1	35.9	57.6	163.8	2015.1	1771.8	*	*	*	*	*	105.1	18.7	13.3	51.8	*
	Pangolin-GD	*	295.7	1860.0	*	2099.9	97.6	295.0	18.3	17.3	8.7	20.3	15.2	3.2	57.0	7.9	13.4	5.0	
	RaTG13	*	*	*	*	*	834.2	219.1	2.5	0.8	3.1	2.1	1.1	*	37.5	*	1.9	*	
	Wuhan-Hu-1	78.1	12.3	13.8	58.0	15.5	1365.4	1088.2	55.2	124.0	44.9	210.3	456.2	22.4	62.0	26.3	55.2	40.6	
	Omicron	928.8	22.4	52.6	116.1	89.7	7071.1	7937.0	196.9	359.0	6729.5	787.5	*	58.0	49.2	49.2	156.3	3715.0	
RBD ELISA EC50(ng/mL)	SARS-CoV-2 clade(1b)	Wuhan-Hu-1	56.1	13.8	15.6	15.1	20.0	18.1	26.5	78.7	8.7	9.6	21.6	41.8	10.7	10.7	9.7	15.7	25.2
		Pangolin-GD	78.6	54.1	130.2	*	*	56.8	33.1	73.4	7.5	9.0	23.2	65.6	8.9	10.1	9.6	14.9	18.4
		Pangolin-GX	708.9	*	*	*	*	52.9	123.5	62.3	44.5	13.4	23.1	*	*	*	*	*	*
	SARS-CoV-1 clade(1a)	RaTG13	144.7	*	*	*	*	41.2	129.2	66.3	27.1	15.6	24.7	61.2	*	35.4	*	58.3	*
		BJ01	41.7	9.9	17.3	20.7	26.4	39.0	26.9	45.4	11.1	8.3	11.5	79.0	7.8	7.1	8.5	24.7	15.3
		PC4-127	52.9	12.5	15.1	14.6	29.6	36.7	12.9	44.1	7.1	7.3	13.5	64.9	8.3	5.6	7.3	10.0	9.9
		Sin852	71.4	16.4	29.2	28.8	43.5	1627.4	15.2	47.5	12.5	11.2	14.9	*	8.1	9.6	10.5	10.0	42.5
		WV1	57.7	32.8	247.3	272.9	*	78.1	10.6	45.9	7.9	11.2	11.5	116.0	9.5	8.1	10.4	12.1	17.8
		LYRa11	113.5	39.4	854.2	*	*	91.4	51.7	64.6	21.1	19.2	18.0	98.9	19.1	11.3	15.5	32.8	24.6
		Rs7327	53.7	41.8	20.9	241.9	*	91.1	15.1	72.7	8.3	8.9	14.7	82.0	9.7	13.4	15.6	26.2	18.2
		GZ-C	116.2	13.6	43.5	33.6	34.2	34.3	23.7	52.5	14.2	13.7	13.2	97.3	15.4	10.3	12.1	18.1	17.0
		Urbani	139.3	33.4	464.6	58.7	91.1	1221.0	48.3	81.0	18.4	13.5	29.5	64.8	10.1	13.0	14.3	61.7	16.6
		Rs4231	99.6	*	*	*	*	*	119.7	81.9	17.1	9.4	17.8	38.1	7.2	50.3	38.3	38.8	24.8
	Africa/Europe BatCoV clade(3)	BM48-31	*	*	*	*	*	64.7	585.4	190.5	86.8	40.7	*	82.9	55.9	27.3	17.5	118.4	*
		BtKY72	*	*	*	*	*	75.3	60.9	57.6	14.7	12.6	21.2	77.1	14.0	13.8	12.9	27.0	52.9
		Shaanxi2011	*	*	*	*	*	41.9	113.3	81.7	34.4	24.9	30.8	*	*	*	*	*	*
	Asia BatCoV clade(2)	YN2013	*	*	*	*	*	44.2	39.5	83.1	40.1	21.7	66.4	*	*	*	*	*	*
		Rp3	*	*	*	*	*	37.3	1.5	76.1	43.6	35.8	19.7	*	*	*	*	*	*
		Rs4247	*	*	*	*	*	22.9	87.7	*	31.7	26.4	30.5	323.8	*	*	*	*	*
		ZC45	*	*	*	*	*	44.3	47.9	73.1	30.3	118.3	46.1	*	*	*	*	*	*
		Anlong112	*	*	*	*	*	39.6	41.0	139.8	49.6	39.1	149.2	*	*	*	*	*	*
		SC2018	*	*	*	*	*	42.0	44.8	174.6	28.2	15.7	60.4	*	*	*	*	*	*
		ZXC21	*	*	*	*	*	24.4	72.6	*	28.9	51.8	63.4	*	*	*	*	*	*

b

c

Fig. 4 | Potency and breadth of selected sarbecovirus neutralizing antibody drug candidates.

a, The sarbecovirus neutralization and binding capability (half-maximum effective concentration, EC50) of selected potent broad-spectrum neutralizing antibodies. *: >10,000 ng/mL for IC50, or >2,000 ng/mL for EC50. **b**, Structural model of the non-competitive broad sarbecovirus neutralizing antibodies BD55-3500 (group F2, in complex of Omicron RBD) and BD55-5840 (group E1, in complex of Omicron RBD). **c**, Structural model of the non-competitive broad sarbecovirus neutralizing antibodies BD55-3372 (group F3, in complex of Delta RBD) and BD55-3546 (group E1, in complex of Delta RBD).

Extended Data Fig. 1 | Neutralization titre of plasma specimens from SARS convalescents vaccinated with 3 doses of SARS-CoV-2 vaccine.

a, Half-maximal neutralization titres (NT50) of plasma against SARS-CoV-2 with D614G mutant (D614G) and SARS-CoV-1 (SARS) pseudovirus, for SARS convalescents before and after the third dose vaccination (n=18). **b**, Scatter plot showing the correlation between plasma NT50 against D614G pseudovirus and SARS pseudovirus for SARS convalescents before (red) and after (blue) the third dose vaccination (n=18). Pearson's correlation coefficient is labeled. **c**, NT50 of plasma against different SARS-CoV-2 variants authentic virus, for SARS convalescents before and after the third dose vaccination (n=18). Statistical significance in a, c was determined by two-tailed Wilcoxon signed rank test (**p<0.01, *p<0.05). NT50 values are displayed as geometric mean $\pm$ s. d. in the log10 scale.

Extended Data Fig. 2 | FACS of SARS-CoV-1 RBD and SARS-CoV-2 RBD cross-binding B cells.

The gating strategy for sorting SARS-CoV-1-RBD⁺/SARS-CoV-2-RBD⁺ single memory B cells. Numbers next to outlined areas indicate percentage of cells in the gate. Sorting of the PBMCs from SARS convalescents that received 3 doses of the SARS-CoV-2 vaccine are shown.

Extended Data Fig. 3 | Escape scores projection of top RBD escaping hotspots.

Shades of red indicate normalized site total escape scores of the representative residues for each antibody inferred from yeast display deep mutational screening.

Extended Data Fig. 4 | Projection of ELISA reactivity against 22 sarbecovirus RBD.

a-e, Shades of red indicate ELISA OD450 for each antibody against various sarbecovirus clades. (**a**, SARS-CoV-1 variants. **b**, SARS-CoV-1-related sarbecovirus. **c**, SARS-CoV-2 related sarbecovirus. **d**, Africa/Europe batcoronavirus. **e**, Asian non-ACE2-utilizing batcoronavirus.)

Extended Data Fig. 5 | Neutralization potency for NAbs of each epitope group.

a-g, Half maximal inhibitory concentration (IC₅₀) of antibodies against different sarbecovirus determined by pseudovirus neutralization assay. The IC₅₀ values are shown as geometric mean $\pm$ s. d. in log₁₀ scale. Dashed lines show the detection limit, which is from 0.0005 μ g/mL to 10 μ g/mL. Number of antibodies n = 68, 49, 61, 45, 53, 27, 31, 23, 126, 57 for epitope group A, B, C, D, E1, E2, E3, F1, F2, F3, respectively (except for **f**). **a**, SARS-CoV-2 with D614G mutation. **b**, SARS-CoV-1 (HKU-39849). **c**, SARS-CoV-2 Omicron (BA.1). **d**, SARS-CoV-2 Omicron (BA.1.1). **e**, SARS-CoV-2 Omicron (BA.2). **f**, RaTG13, n = 50, 38, 47, 41, 52, 27, 31, 23, 125, 56 for epitope group A, B, C, D, E1, E2, E3, F1, F2, F3, respectively. **g**, Pangolin-GD.

Extended Data Fig. 6 | Structures of individual broad sarbecovirus neutralizing antibody drug candidates.

a, BD55-3546 Fab in complex of Delta RBD. **b**, BD55-5840 Fab in complex of Omicron RBD. **c**, BD55-3500 Fab in complex of Omicron RBD. **d**, BD55-3372 Fab in complex of Delta RBD. Residues on the binding interface are marked.

Extended Data Fig. 7 | Averaged escape maps of BA.1-neutralizing and non-neutralizing antibodies in epitope group E1 and F3.

Height of each amino acid in the escape maps represents its mutation escape score. Residues are colored corresponding to their chemical properties. Mutated sites in Omicron variants (including BA.1, BA.1.1 and BA.2) are marked in bold.

Extended Data Fig. 8 | Cryo-EM structure of BD55-3152 Fab in complex of SARS-CoV-1 RBD.

Residues on the binding interface are marked.

Extended Data Fig. 9 | Averaged escape maps of antibodies in epitope group A-D.

Height of each amino acid in the escape maps represents its mutation escape score. Residues are colored corresponding to their chemical properties. Mutated sites in Omicron variants are marked in bold.

Extended Data Fig. 10 | Projection of DMS predicted escaping of sarbecovirus RBD.

a-e, Gray points represent antibodies predicted to be escaped from DMS data. Deletions and insertions on RBD are not considered. (**a**, SARS-CoV-1 variants. **b**, SARS-CoV-1-related sarbecovirus. **c**, SARS-CoV-2 related sarbecovirus. **d**, Africa/Europe batcoronavirus. **e**, Asian non-ACE2-utilizing batcoronavirus.)